Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study
Key Points
Key points are not available for this paper at this time.
Abstract
Merck Sharp & Dohme, National Institutes of Health, and National Cancer Institute.
AI에게 질문
Like
Bookmark
Share
View Full Paper
AI에게 질문
Like
Bookmark
Share
View Full Paper
Belzutifan for patients with von Hippel-Lindau disease-associated CNS haemangioblastomas (LITESPARK-004): a multicentre, single-arm, phase 2 study | Synapse